Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

Salvatore Petta, Vincenza Calvaruso, Vito Di Marco, Antonio Craxi, Cristina Bertelli, Giuseppina Pisano, Rosa Lombardi, Federica Iuculano, Paolo Francione, Annalisa Cespiati, Giordano Sigon, Fracanzani Anna Ludovica, Fargion Silvia, Erika Fatta, Federico Silvia, Gerlando Gibilaro, Luciano Crapanzano

Risultato della ricerca: Articlepeer review

1 Citazioni (Scopus)

Abstract

Background: Chronic hepatitis C (CHC) is associated with hepatic steatosis, related to both a direct viral action and metabolic features. Vice-versa data on hepatic steatosis after viral eradication by direct-acting antiviral agents (DAA) are undefined although the presence of metabolic alterations could strongly influence the occurrence of steatosis as in NAFLD. The controlled attenuation parameter (CAP) (FibroscanⓇ) allows the qualitative and quantitative evaluation of fatty liver. Aim: to evaluate in patients with CHC whether hepatic steatosis diagnosed by CAP modifies after DAAs-induced sustained virologic response (SVR). Methods: Data were collected the day of DAAs therapy starting and six months after SVR. CAP ≥ 248 dB/m defined the presence of steatosis. Results: 794 CHC SVR patients referring to 2 Italian Units were enrolled. Mean age was 64 ± 16 ys, 50% males, BMI 25.4 ± 4 kg/m2, genotype type-1 in 73%, type-3 in 8%. Prevalence of hepatic steatosis at baseline was 32% by US and 46% by CAP. De novo steatosis developed in 125 (29%), resolution in 122 (30%). At multivariate analysis de novo steatosis was independently associated with male sex (OR 1.7, CI 95% 1.09–2.67; p = 0.02) and baseline BMI (for unit increase OR 1.19, CI 95%1.11–1.29; p < 0.001). Baseline BMI (for unit increase OR 0.47, CI 95% 0.25–0.89; p = 0.02) and triglycerides (for unit increase OR 0.93, CI 95% 0.87–0.99; p = 0.03) prevented steatosis resolution after therapy. Conclusions: after SVR de novo steatosis and resolution of baseline steatosis are closely related to the presence of metabolic comorbidities.
Lingua originaleEnglish
Numero di pagine7
RivistaDigestive and Liver Disease
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2721???
  • ???subjectarea.asjc.2700.2715???

Fingerprint

Entra nei temi di ricerca di 'Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)'. Insieme formano una fingerprint unica.

Cita questo